116 related articles for article (PubMed ID: 37804699)
1. Synthesis by diastereomeric resolution, biochemical evaluation and molecular modelling of chiral 3-hydroxyl b-lactam microtubule-targeting agents for the treatment of triple negative breast and chemoresistant colorectal cancers.
McLoughlin EC; Twamley B; O'Brien JE; Hannon Barroeta P; Zisterer DM; Meegan MJ; O'Boyle NM
Bioorg Chem; 2023 Dec; 141():106877. PubMed ID: 37804699
[TBL] [Abstract][Full Text] [Related]
2. β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells.
Malebari AM; Fayne D; Nathwani SM; O'Connell F; Noorani S; Twamley B; O'Boyle NM; O'Sullivan J; Zisterer DM; Meegan MJ
Eur J Med Chem; 2020 Mar; 189():112050. PubMed ID: 31954879
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones.
Malebari AM; Duffy Morales G; Twamley B; Fayne D; Khan MF; McLoughlin EC; O'Boyle NM; Zisterer DM; Meegan MJ
Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145265
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4.
Malebari AM; Wang S; Greene TF; O'Boyle NM; Fayne D; Khan MF; Nathwani SM; Twamley B; McCabe T; Zisterer DM; Meegan MJ
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832901
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells.
Wang S; Malebari AM; Greene TF; Kandwal S; Fayne D; Nathwani SM; Zisterer DM; Twamley B; O'Boyle NM; Meegan MJ
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513912
[TBL] [Abstract][Full Text] [Related]
6. 3-Vinylazetidin-2-Ones: Synthesis, Antiproliferative and Tubulin Destabilizing Activity in MCF-7 and MDA-MB-231 Breast Cancer Cells.
Wang S; Malebari AM; Greene TF; O'Boyle NM; Fayne D; Nathwani SM; Twamley B; McCabe T; Keely NO; Zisterer DM; Meegan MJ
Pharmaceuticals (Basel); 2019 Apr; 12(2):. PubMed ID: 30979033
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones.
O'Boyle NM; Greene LM; Bergin O; Fichet JB; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
Bioorg Med Chem; 2011 Apr; 19(7):2306-25. PubMed ID: 21397510
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.
Zhou P; Liang Y; Zhang H; Jiang H; Feng K; Xu P; Wang J; Wang X; Ding K; Luo C; Liu M; Wang Y
Eur J Med Chem; 2018 Jan; 144():817-842. PubMed ID: 29306206
[TBL] [Abstract][Full Text] [Related]
9. β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.
Malebari AM; Greene LM; Nathwani SM; Fayne D; O'Boyle NM; Wang S; Twamley B; Zisterer DM; Meegan MJ
Eur J Med Chem; 2017 Apr; 130():261-285. PubMed ID: 28254699
[TBL] [Abstract][Full Text] [Related]
10. Application of 2D EXSY and qNMR Spectroscopy for Diastereomeric Excess Determination Following Chiral Resolution of β-Lactams.
McLoughlin EC; O'Brien JE; Trujillo C; Meegan MJ; O'Boyle NM
ChemistryOpen; 2023 Jun; 12(6):e202200119. PubMed ID: 35876400
[TBL] [Abstract][Full Text] [Related]
11. β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand.
O'Boyle NM; Pollock JK; Carr M; Knox AJ; Nathwani SM; Wang S; Caboni L; Zisterer DM; Meegan MJ
J Med Chem; 2014 Nov; 57(22):9370-82. PubMed ID: 25369367
[TBL] [Abstract][Full Text] [Related]
12. The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.
Greene LM; Nathwani SM; Bright SA; Fayne D; Croke A; Gagliardi M; McElligott AM; O'Connor L; Carr M; Keely NO; O'Boyle NM; Carroll P; Sarkadi B; Conneally E; Lloyd DG; Lawler M; Meegan MJ; Zisterer DM
J Pharmacol Exp Ther; 2010 Nov; 335(2):302-13. PubMed ID: 20699436
[TBL] [Abstract][Full Text] [Related]
13. Optically active 1,3,4,4-tetrasubstituted β-lactams: synthesis and evaluation as tumor cell growth inhibitors.
Pérez-Faginas P; Aranda MT; García-López MT; Francesch A; Cuevas C; González-Muñiz R
Eur J Med Chem; 2011 Oct; 46(10):5108-19. PubMed ID: 21885166
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of antiproliferative microtubule-destabilising combretastatin A-4 piperazine conjugates.
O'Boyle NM; Ana G; Kelly PM; Nathwani SM; Noorani S; Fayne D; Bright SA; Twamley B; Zisterer DM; Meegan MJ
Org Biomol Chem; 2019 Jun; 17(25):6184-6200. PubMed ID: 31173031
[TBL] [Abstract][Full Text] [Related]
15. Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.
Carr M; Greene LM; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
Eur J Med Chem; 2010 Dec; 45(12):5752-66. PubMed ID: 20933304
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships OF N-methylthiolated beta-lactam antibiotics with C3 substitutions and their selective induction of apoptosis in human cancer cells.
Kuhn DJ; Wang Y; Minic V; Coates C; Reddy GS; Daniel KG; Shim JY; Chen D; Landis-Piwowar KR; Miller FR; Turos E; Dou QP
Front Biosci; 2005 May; 10():1183-90. PubMed ID: 15769617
[TBL] [Abstract][Full Text] [Related]
17. Potent Antitumor Activities and Structure Basis of the Chiral β-Lactam Bridged Analogue of Combretastatin A-4 Binding to Tubulin.
Zhou P; Liu Y; Zhou L; Zhu K; Feng K; Zhang H; Liang Y; Jiang H; Luo C; Liu M; Wang Y
J Med Chem; 2016 Nov; 59(22):10329-10334. PubMed ID: 27805821
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents.
Greene TF; Wang S; Greene LM; Nathwani SM; Pollock JK; Malebari AM; McCabe T; Twamley B; O'Boyle NM; Zisterer DM; Meegan MJ
J Med Chem; 2016 Jan; 59(1):90-113. PubMed ID: 26680364
[TBL] [Abstract][Full Text] [Related]
19. Stereochemical preference toward oncotarget: Design, synthesis and in vitro anticancer evaluation of diastereomeric β-lactams.
Olazarán-Santibáñez F; Bandyopadhyay D; Carranza-Rosales P; Rivera G; Balderas-Rentería I
Oncotarget; 2017 Jun; 8(23):37773-37782. PubMed ID: 28562328
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting β-lactam combretastatins.
O'Boyle NM; Greene LM; Keely NO; Wang S; Cotter TS; Zisterer DM; Meegan MJ
Eur J Med Chem; 2013 Apr; 62():705-21. PubMed ID: 23454513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
